Abbott/Jago collaborating on extended-release zileuton (Zyflo) for asthma; 1998 NDA is planned.
ABBOTT/JAGO TWICE-DAILY ZILEUTON NDA FOR ASTHMA SLATED FOR 1998, Jago's parent company SkyePharma disclosed Jan. 20. Jago, acquired by SkyePharma in May, is collaborating with Abbott on an extended-release formulation of Abbott's recently launched leukotriene inhibitor Zyflo (zileuton). The Geomatrix formulation of zileuton is "entering Phase III clinical studies" and "a submission for regulatory approval is expected to be made in 1998," SkyePharma said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth